PUBLICATIONS

1 – RJ Morrow, AH Allam, B Yeo, S Deb, C Murone, Lim E, CN Johnstone, M Ernst. Paracrine IL‐6 signalling confers proliferation between heterogeneous inflammatory breast cancer subclones. Cancers. 2022;14(9);2292.
2 – Berthelet J, Foroutan M, Bhuva DD, Whitfield H, El-Saafin F, Cursons J, Serrano A, Merdas M, Lim E, Charafe-Jauffret E, Ginestier C, Ernst M, Hollande F, Anderson R, Pal B, Yeo B, Davis MJ, Merino D. Computational screening of anti-cancer drugs identifies a non-BRCA1-dependent cisplatin-sensitive signature in breast cancer. Cancers. 2022;14(10):2404.
3 – N Portman, Lim E. A new sophistication for breast cancer PDX. Nature Cancers. 2022;3;138–40.
4 – LR Haggstrom, JL Vardy, E Carson, D Segara, Lim E*, BE Kiely*. Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review. Cancers. 2022;14(4);920.
5 – L Brown, J Achinger-Kawecka, N Portman, S Clark, C Stirzaker*, Lim E*. Epigenetic Therapies and Biomarkers in Breast Cancer. Cancers. 2022;14(3):474.
6 – Dinh P, … Lim E, White M, Mann GB, Pathmanathan N. Impact of the EndoPredict genomic assay on treatment decisions for estrogen receptor positive early breast cancer patients: benefits of physician selective testing. Breast Cancer Research Treatment. 2022 Feb;191(3):501-11.
7 – Brown L*, Meredith T*, … Arnott C*, Lim E*. Heart failure therapies for the prevention of HER2-monoclonal antibody mediated cardiotoxicity. Cancers. 2021 Nov 3;13(21):5527.
8 – N Portman, J Chen, E Lim. MDM2 as a rational target for intervention in CDK4/6 inhibitor resistant, hormone receptor positive breast cancer. Frontiers Oncology. 2021 Nov 3;11:777867.
9 – Nguyen A, … Lim E, Emmett L. Diagnostic value of 68Ga-DOTATATE PET-CT imaging for staging of ER+/PR+ HER2- breast cancer patients with metastatic disease: comparison with conventional imaging with bone scan, diagnostic CT and 18F-FDG PET-CT in a prospective pilot trial. Journal of Medical Imaging and Radiation Oncology. 21 Oct 2021.
10 – S Kumar, A Freelander, E Lim . Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic. Cancers. 2021 Oct 3:13;4972
11 – Du Q, … Lim E, et al. DNA methylation is required to maintain both DNA replication timing precision and 3D genome integrity. Cell Reports. 2021 Sep 21;36(12):109722
12 – Wu SZ, … Lim E, Lundeburg J, Perou CM, Swarbrick A. An integrated multi-omic cellular atlas of human breast cancers. Nature Genetics. 2021 Sep 6;53:1334–47
13 – Chen J, Colosimo M, Lim E. The management of HER2-positive early breast cancer: current and future therapies. Asia Pacific J Clin Oncol. 2021 Sep 1;17:S6:1-12
14 – Aziz D, … Lim E, Caldon CE. Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. NPJ Cancer. 2021 Aug 31;7:111
15 – Alves CL, … Lim E, Ditzel HJ. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nature Comms. 2021 Aug 25;12(1):5112
16 – Chew NJ, … Lim E, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast Cancer Research. 2021 Aug 3;23(1):82
17 – Ardolino L, … Lim E. Paclitaxel-induced Pneumonitis in Early Breast Cancer: A Single Institution Experience. Frontiers Oncology.
18 – Wu SZ, … Lim E, Swarbrick, A. Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Biol. 2021 May 10;13(1):81
19 – Freelander A, … Lim E. Molecular biomarkers for contemporary therapies in hormone receptor positive breast cancer. Genes. 2021 Feb 17;12(2):285
20 – Hickey TE, Selth LA, Chia KM, Milioli HH, Roden D, Laven-Law G, Jindal S, Hui M, Ebrahimie E, Birrell SN, Stelloo S, Caldon CE, Finlay-Schultz J, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer. Nature Medicine. Jan 2021.
21 – De Boer R, Hui R, Lim E, Yeo B, N Zdenkowski. Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer. Asia Pacific J Clin Oncol. 2020 Nov;16 Suppl 5:3-14.
22 – Chia KM, Freelander A, Kumar S, Portman N, Lim E. Estrogen receptor positive breast cancer patient derived xenograft models in translational research. Current Opinion in Endocrine and Metabolic Research. 23rd Oct 2020.
23 – Portman N*, Milioli HH*, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Segara D, Parker A, Swarbrick A, Haupt A, Haupt Y, Tilley WD, Swarbrick A, Caldon CE*, Lim E*. Synergistic targeting of estrogen-receptor positive breast cancers by MDM2 inhibition in combination with endocrine therapy or CDK4/6 inhibition. Breast Cancer Research. 2020 Aug 12;22(1):87.
24 – Wu SZ, Roden D, Wang CF, Cazet A, Al-Eryani G, Harvey K, Holliday H, Murphy K, Pereira B, Bartonicek N, Hou R, Torpy J, Junankar S, Hui M, Gluch L, Beith J, Parker A, Robbins E, Segara D, Mak C, Cooper C, Warrier S, Powell J, O’Toole S, Cox T, Timpson P, Forrest A, Lim E, Liu XS, Swarbrick A. Single-cell RNA sequencing of triple-negative breast cancers reveals novel functionally distinct subclasses of stromal cells. Embo J. 2020 Oct 1;39(19).
25 – Light M, McFarlane T, Ives A, Shah B, Lim E, Grossmann M, Zajac JD, Cheung AS. Testosterone therapy considerations in estrogen, progesterone and androgen receptor positive breast cancer in a transgender male. Clinical Endo. 2020 Sep;93(3):355-7.
26 – Baker LA, Holliday H, Roden D, Krisp C, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Sankaranarayanan G, Law AMK, McFarland A, Simpson PT, Lakhani S, Dodson E, Selinger C, Anderson L, Samimi G, Hacker NF, Lim E, Ormandy CJ, Naylor MJ, Simpson K, Nikolic I, O’Toole S, Kaplan W, Cowley MJ, Carroll JS, Molloy M, Swarbrick A. Proteogenomic analysis of Inhibitor of Differentiation in basal-like breast cancer. Breast Cancer Research. 22(1):63, 11 Jun 2020.
27 – Milioli HH, Alexandrou S, Lim E, Caldon C. Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. Endocrine-Related Cancer. 1 Feb 2020.
28 – Tadesse S. Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, Wang S. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discovery Today. 10 Dec 2019.
29 – Chen J*, Easwaralingam N*, Warrier S, Mak C, Carson E, Ong A, Snook K, Middleton K, Parker A, Spillane A, Mann B, Lim E, Segara D. Window of Opportunity Treatment in Breast Cancer. ANZ J Surg. 26 Nov 2019.
30 – Field AS, Raymond WA, Rickard M, Arnold L, Brachtel EF, Chaiwun B, Chen L, Di Bonito L, Kurtycz DFI, Lee AHS, Lim E, Ljung BM, Michelow P, Osamura RY, Pinamonti M, Sauer T, Segara D, Tse G, Vielh P, Chong PY and Schmitt F. The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytology. Acta Cytol. 2019 May 21:1-17.
31 – Chi D, Singhal H, Li L, Xiao TF, Liu WH, Pun M, Jeselsohn R, He H, Lim E, Vadhi R, Rao P, Long H, Garber J, Brown M. Estrogen Receptor Signaling is Reprogrammed During Breast Tumorigenesis.Proc Natl Acad Sci USA. 2019 May 20.
32 – Young AR, Duarte JD, Coulson R, O’Brien M, Deb S, Lopata A, Behren A, Mathivanan S, Lim E, Meeusen E. Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes.Cancers. 2019 May 16;11(5).
33 – Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O’Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.Breast Cancer Res. 2019,21;21(1):43.
34 – Grossmann M, Ramchand SK, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Summary Position Statement. Med J Aus. 2019; 211(5):224-229.
35 – Alexandrou S, George SM,Ormandy CJ, Lim E, Oakes SR,Caldon CE. The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. Int. J. Mol. Sci. 2019, 20(3), 667.
36 – Chia K,Milioli H, Portman N, Laven-Law G, Coulson R,Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E. Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocr Rel Cancer. 2019 Feb 1;26(2):251-264.
37 – Portman N, Alexandrou S, Carson EK, Wang S, Lim E, Caldon CE*. Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer. Endocr Rel Cancer. 2019:26, R15–30.
38 – Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, Lynch J, Friedlander M, Lee CK. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2018 Nov 21.
39 – Boyle F, Beith J, Burslem K, de Boer R, Hui R, Lim E McCarthy N, Redfern A, Woodward N. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on current treatment paradigm. Asia Pacific J Clin Oncol. 2018 Oct;14 Suppl 4:3-11.
40 – Lim E, Beith J, Boyle F, de Boer R, Hui R, McCarthy N, Redfern A, Wade T, Woodward N. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.Asia Pacific J Clin Oncol. 2018 Oct;14 Suppl 4:12-21.
41 – Saunders C, Jassal S, Lim E. Breast Cancer: The Facts. Oxford University Press.. 2nd Edition 2018.
42 – Cazet AS, Hui MH, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng NT, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R,Lim E, Timpson P, O’Toole S, Watkins DN, Cox TR, Samuel M, Martin M, Swarbrick A. Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer. Nature Comms. 2018 Jul 24;9(1):2897.
43 – Papachristou E, Kishore K, Holding A, Harvey K, Roumeliotis T, Chilamakuri C, Omarjee S, Chia KM, Swarbrick A, Lim E Markowetz F, Eldridge M, Siersbaek R, D’Santos C, Carroll J. Quantitative Multiplexed Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins (qPLEX-RIME) for monitoring the dynamics of chromatin-associated complexes. Nature Comms. 2018 Jun 13;9(1):2311.
44 – Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol. 2018 Sep;89(3):280-296.
45 – Hastie R, Lim E, Slukass P, Campbell L, Horne A, Ellett L, Hannan N, Brownfoot F, Kaitu’u-Lino TJ, Tong S. Vinorelbine potently induces placental cell death, does not harm fertility and is a potential oral treatment for ectopic pregnancy. EBioMedicine. 2018;29:166-76.
46 – Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Larsson C, Eriksson P, Lehn S, Reid S, Saal LH, Anderberg C, Cortez E, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, Sjölund J, Orimo A, Höglund M, Rydén L, Moch H, Scott AM, Eriksson U, Pietras K. Microenvironmental control of breast cancer subtype elicited by paracrine platelet derived growth factor-CC signaling. Nature Medicine. 2018;24(4):463-73.
47 – Robinson DH, Churilov L, Lin NU, Lim E, Seah D. Attitudes of patients with metastatic cancer towards research biopsies. APac JCO. Nov 6 2017.
48 – Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS. Neoadjuvant Interferons: Critical for effective PD-1 based immunotherapy in TNBC. Cancer Immunology Research. Aug 28 2017.
49 – Meeusen E, Lim E, Mathivanan S. Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy. Proteomics. Jul 17 2017.
50 – Lim E, Johnson SF, Geyer M, Serra V, Shapiro GI. Sensitizing HR-proficient cancers to PARP inhibitors. Molecular Cellular Oncology. Mar 3 2017.
51 – Law A, Lim E, Ormandy CJ, Gallego-Ortega D. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endo Rel Cancer. 2017;24(4):R123-44
52 – Dreijerink K, Groner AC, Vos E, Font-Tello A, Gu L, Chi D, Reyes J, Cook J, Lim E, Lin CY, de Laat W, Rao P, Long H and Brown M. Enhancer-mediated oncogenic function of the MEN1 tumor suppressor in breast cancer. Cell Reports. 2017;18(10):2359-72
53 – Haupt S, Vijayakumaran R, Panimaya J, Burgess A, Lim E, Haupt Y. The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol. Jan 17 2017.
54 – Portman N, Wahlroos S, Parker A, Segara D, Lim E. Endocrine therapy for breast cancer: A Renaissance. The Endocrinologist. Dec 2016.
55 – Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. Nov 22 2016.
56 – Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kachupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D’Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild type and mutated models of triple negative breast cancer. Cell Reports. 2016;17(9):2367-2381
57 – Lim E, Tarulli G, Portman N, Hickey T, Tilley W, Palmieri C. Pushing Estrogen Receptor around in breast cancer. Endo Rel Cancer. 2016;23(12):T227-T241
58 – Lim E, Palmieri C, Tilley W. Renewed interest in the Progesterone Receptor in Breast Cancer. British J Cancer. 22nd Sep 2016
59 – Ramchand S, Lim E, Grossmann M. Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: How should the skeletal and vascular side effects be assessed and managed?. Clinical Endo 6th Aug 2016.
60 – Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical Overview of MDM2/X targeted therapies. Frontiers Onc 2016:6:1-7.
61 – Neupane M, Clark A, Landini S, Birkbak N, Eklund A, Lim E, Culhane A, Barry W, Schumacher S, Beroukhim R, Szallasi Z, Vidal M, Hill DE, Silver D. MECP2 Is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy. Cancer Discovery. 2016:6(1):45-58.
62 – Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 2015 Oct 27;6:8746.
63 – Wang YB, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ. CDK7-dependent transcriptional addiction in Triple-Negative breast cancer. Cell 2015;163(1):174-86.
64 – Samanta S, Sun H, Goel HL, Pursell B, Chang C, Khan A, Greiner DL, Cao S, Lim E, Shultz LD, Mercurio AM. IMP3 promotes stem-like properties in Triple-Negative breast cancer by regulating SLUG. Oncogene 2015 May 18.
65 – Chang C, Goel HL, Gao H, Pursell B, Shultz LD, Greiner DL, Ingerpuu S, Patarroyo M, Cao S, Lim E, Mao J, McKee KK, Yurchenco PD, Mercurio AM. A Laminin 511 Matrix is regulated by TAZ and functions as the ligand for the a6Bb1 integrin to sustain breast cancer stem cells. Genes & Devt. 2015;29(1):1-6.
66 – Chia KM, O’Brien M, Brown M, Lim E. Targeting the androgen receptor in breast cancer. Current Oncology Reports. . 2015;17(2):427-34.
67 – Hu Y, Petit A, Ficarro S, Toomire KJ, Xie A, Lim E, Cao SA, Park E, Eck MJ, Scully R, Brown M, Marto JA, Livingston DM. PARP1-driven Poly-ADP-ribosylation regulates BRCA1 function in homologous recombination mediated DNA repair. Cancer Discovery. 2014;4(12):1430-47.
68 – Lim E, Goel S, Winer EP. Chapter title: Adjuvant chemotherapy in breast cancerSpringer. NYC.
69 – Lu G, Zhang Q, Huang Y, Song JX, Tomaino R, Ehrenberger T, Lim E, Liu WB, Bronson RT, Bowman M, Dillon DA, Gygi SP, Mills G, Richardson AL, Signoretti S, Yaffe MB, Kaelin WG Jr. Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell. 2014:26(2):222-34.
70 – Lim E & Lin NU. Updates on the management of breast cancer brain metastases. Oncology. 2014:28(7):572-8.
71 – Lim E, Ni M, Cao SA, Hazra A, Tamimi R, Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Current Breast Cancer Reports. 2014:6(2):71-8.
72 – Wang YB, Lee YM, Huang A, Lim E, Min JX, Li L, Choi C, Xiang Y, Baitsch L, Stegmeier F, Schlegel R, Gray NS, Mitchison TJ, Zhao JJ. The oncogenic protein kinase MELK is essential for mitotic progression in basal-like breast cancer cells. Elife. 2014:May20:3:e01763.
73 – Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen YW, Mai JH, Shen HF, Hu DZ, Adoro S, Hu B, Song MY, Tan C, Landis MD, Ferrari M, Shin SJ, Brown M, Chang JC, Liu XS, Glimcher LH. XBP1 promotes triple negative breast cancer by controlling the HIF1α transcriptional program. Nature. 2014:508(7494):103-7.
74 – McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, Bronson RT, Beroukhim R, Polyak K, Brown M, Kuperwasser C, Cichowski K. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 2013:24(3):365-78.
75 – Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, Chen X, Liu XS, Brown M, Lim B, Weinberg RA. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013:24(3):347-64.
76 – Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Fu X, Schiff R, Brown M, Brugge JS. PDEF Promotes Luminal Differentiation 1 and acts as a survival factor for ER positive breast cancer cells. Cancer Cell. 2013;23;753–67.
77 – Tichy J, Lim E, Anders CK. Adolescent and young adult breast cancer: A review with a focus on biology. J Natl Compr Canc Netw. 2013:11(9):1060-9.
78 – Ni M, Chen YW, Fei T, Li D, Lim E, Liu XS, Brown M. Amplitude modulation of androgen signaling by c- MYC. Genes Dev. 2013:27(7):734-48.
79 – Lim E, Metzger O, Winer EP. Natural history of hormone receptor positive breast cancer. Oncology. 2012:26(8):688-94.
80 – Lim E & Lin NU. New insights and emerging therapies in breast cancer brain metastases. Oncology. 2012:26(7):652-9.
81 – Shen R, Zhou A, Kim E, Lim E, Habelhah H, Hahn W. IKKε phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol. 2012:32(23):4756-68.
82 – Lim E, Ni Min, Hazra A, Tamini R, Brown M. Elucidating the role of androgen receptors and breast cancer. Clinical Investigation. 2012:2(10):1003-11.
83 – Lim E & Winer EP. Current challenges in HER2-positive breast cancer. ASCO educational book. 2011:14-20.
84 – Lim E & Winer EP. Adjuvant chemotherapy in luminal breast cancers. Breast. 2011:20(S3):S128-31.
85 – Lim E & Winer EP. Will preoperative trials change future clinical practice? Clinical Investigation. 2011:1(1):59-73.
86 – Ni M, Chen YW, Lim E, Bailey ST, Imai Y, Liu XS, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011:20(1):119-31.
87 – Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, et al. The BH3-mimetic ABT-737 sensitizes BCL-2 expressing breast cancers to chemotherapy, implicating BCL-2 as a predictive biomarker. Proc Natl Acad Sci USA. 2011:109(8):2766-71.
88 – Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE & Smyth GK. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010:26(17):2176-82.
89 – Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010:12(2):R21.
90 – Lim E, Vaillant F, Wu D, Forrest N, Pal B, Hart A, et al. Aberrant luminal progenitors as a likely target population for basal tumor development in BRCA1 mutation carriers. Nature Med. 2009:15(8):842-4.
91 – Lim E, Thomson BNJ , Heinz S, Chao M, Gunawardana D, Gibbs P. Optimising the approach to patients with potentially resectable liver metastases from colorectal cancer. ANZ J Surg. 2007:77(11):941-7.
92 – Lim E, Rosenthal M. Diagnosing cancer: changing patterns of care. Intern Med J. 2007:37(2):124-6.
93 – Lim E, Browning J, MacGregor D, Davis ID, Cebon JS. Antigen expression in desmoplastic melanoma: a comparison of cancer testis antigen with differentiation antigen expression. Melanoma Research. 2006:16(4):347-55.
94 – Rodrigues J, Lim E, McLaughlin S, Faragher I, Skinner I, Chao M, Chapman M, Gibbs P. The influence of language spoken on colorectal cancer diagnosis and management. ANZ J Surg. 2006:76:671-3.
95 – Lim E, Johns J, McLaughlin S, Faragher I, Skinner I, Chao M, Gibbs P. Subsite-specific colorectal cancer in diabetic and nondiabetic patients. Cancer Epidemiol Biomarkers Prev 2005:14(6):1579-82.
96 – Lim E, Roberts L, Wicks I. Intracardiac thrombosis complicating antiphospholipid antibody syndrome. Intern Med J. 2004:34(3):135-7.